Skippet, a pioneer in AI and Natural Language Processing (NLP), is changing the way people interact with computers.
“Solving a problem or implementing a solution should be as easy as describing it.” – Jacob, Co-Founder & CEO at Skippet
This week Skippet announced the closing of its $2.2m seed round led by VC fund Neo with participation from Wedbush Ventures, Studio Management, Gaingels, Assure, and prominent US and European angel investors.
Skippet empowers everyone to create custom digital solutions to solve problems without needing to code. Write out your problem in plain English, and Skippet uses its knowledge of your existing systems and integrations, along with state-of-the-art language models to create or modify an application or workflow. This is made possible by Skippet’s proprietary architecture which translates natural language into fit-for-purpose solutions.
More from News
- The Fall Of Showering And The Rise Of Personal Hygiene Apps
- Have You Used The New Meta AI Feature On WhatsApp And Instagram?
- Experts Weigh In On Google Delaying Removal Of Third-Party Cookies Again
- Will TikTok Pull Out Of The US?
- UK’s Top 100 Fastest-Growing Female-Led Businesses Announced
- Will Robots Replace Warehouse Workers?
- UK Graduates Are Now Prioritising Higher-Paying Careers
- World Snooker Championships 2024: An Industry Of Winning Shots
Skippet’s founders believe that, from individuals to large organisations, people should be able to seamlessly customise software in a world where business needs are always changing. Skippet aims to make inflexible and expensive software redundant.
The team was inspired to build Skippet by their experience in helping over 200 organisations (schools & businesses) through the COVID-19 pandemic. The company developed MyMedBot, a no-code platform for digitising COVID-19 communication protocols that automated over 11 million forms. The founders learned from their customers how many people are excluded from modern technology and are stuck with complicated and inflexible tools offered by expensive software vendors.
Headquartered in Luxembourg, the company is fully remote and international, hiring for software development roles across Europe, the UK and the US. The seed round funding will be used to grow the product development team and roll-out Skippet to the company’s 200 MyMedBot customers and beyond. Skippet will be released in private beta in February 2022.